Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Capacity Utilization - Capsules % ・Standalone data |
|
||||||||
| Capacity Utilization - Tablets % ・Standalone data |
|||||||||
| Installed Production Capacity - Capsules Million units/month ・Standalone data |
|||||||||
| Installed Production Capacity - Dry Syrup MT/month ・Standalone data |
|||||||||
| Installed Production Capacity - Tablets Million units/month ・Standalone data |
|||||||||
| Geography-wise Revenue Diversification (Overseas Market) % ・Standalone data |
|||||||||
| Capacity Utilization - Dry Syrup % ・Standalone data |
|||||||||
| Total Products in Portfolio Number of Products ・Standalone data |
|||||||||
| Number of Manufacturing Units Count ・Standalone data |
|||||||||
Documents
Announcements
-
Intimation Of Action Taken Or Order Passed By Regulatory, Statutory, Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (LODR) Regulations, 2015 ("Listing Regulations')
24 Feb - SoP notices alleging Reg 6(1) breach; penalties Rs63,720 each from NSE and BSE; waiver filed 24-Feb-2026.
-
Clarification With Regards To Additional Details Sought In Respect Of Outcome Of Board Meeting Held On 18Th February 2026 Submitted To Exchange On 18Th February 2026
24 Feb - Clarifies board meeting timing and confirms outcome filed within SEBI LODR time on 18 Feb 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
18 Feb - Board appointed Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer on 18 Feb 2026.
- Financial Results For The Quarter Ended 31St December 2025 12 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting
12 Feb - Board approved unaudited standalone results for quarter and half year ended 31 Dec 2025.
Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments